Drugs / Pfizer Bivalent COVID-19 Vaccine
Pfizer Bivalent COVID-19 Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05556720 | Dec 2022 → Jun 2026 overdue | B-cell chronic lymphocytic leukemia, HIV infectious disease, disease related to solid organ transplantation, plasma cell myeloma | Monash University | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pfizer Bivalent COVID-19 Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05556720 ↗ |
| Modality | Messenger RNA (mRNA) | “contains 30 micrograms of a single-stranded, 5'-capped messenger RNA (mRNA)” NCT05556720 ↗ |